1
Results: The median follow-up time of all eligible patients was 58 months.
2
Results: Thirty-two eligible patients were enrolled and twenty-nine were evaluable for response.
3
Results: Twenty-five eligible patients underwent rectal resection with the TSTStarr Plus stapler.
4
Four readers reinterpreted the perfusion scans and chest radiographs of eligible patients.
5
However, despite clear benefit of MVr, many eligible patients are untreated.
6
The remaining eligible patients were followed for 1 year after their initial visit.
7
Methods: This study included 102 eligible patients undergoing VABB and having benign lesions.
8
Ninety-nine eligible patients participated in the study at 3 different types of hospitals.
9
Exposures: All eligible patients had concussions consistent with the Zurich consensus diagnostic criteria.
10
TARGIT-IORT should be discussed with eligible patients when breast conserving surgery is planned.
11
Results: In all, 244 eligible patients were enrolled into the study.
12
Performance was reported as proportions of eligible patients fulfilling adherence criteria.
13
The 40 eligible patients who began chemotherapy are included in the statistical analyses.
14
The eligible patients were exposed versus unexposed general adult ICU survivors.
15
Forty-three out of ninety-one of the eligible patients completed the study.
16
A median of four cycles of Triapine was administered to 19 eligible patients.
